Phase 3 Findings on Neffy for Pediatric Patients with Severe Allergies: A Conversation with Motohiro Ebisawa, MD, PhD
Dr Ebisawa details the findings he recently presented at the 2024 AAAAI annual meeting, including adverse events and next steps for the study.
Needle-free Epinephrine Delivery: Perceptions of Physicians, Patients, and Caregivers
AAAAI 2024. Needle phobia is just one of the barriers to not just using an epinephrine autoinjector but to carrying one at all, according to 2 sets of surveys findings.
New Data Suggest neffy May be Safe, Effective for Treatment of Urticaria Flares
AAAAI 2024. In patients with treatment-resistant chronic spontaneous urticaria, neffy 1 mg and 2 mg resulted in improvement in itch, hives, urticaria, and erythema scores 5 minutes after dosing.
Ethnic Minorities Found More Likely to Require Change in Biologic Therapy for Severe Asthma
New data presented at AAAAI 2024 sheds light on real-world patterns of biologic use in a diverse patient population with severe asthma.
EoE in Children Treated with Dupilumab More Severe at Diagnosis, Study Finds
AAAAI 2024. Dupilumab-treated eosinophilic esophagitis in children was also more often associated with comorbid asthma, according to researchers.
New Research Highlights Specific Allergens that May Predispose Sensitized Children with Asthma to Upper Respiratory Infections
AAAAI 2024. Indoor mouse and cockroach, but not cat and dog, allergen exposure were associated with URI outcomes among children with asthma.
New neffy Data on Clinical Efficacy Presented at 2024 AAAAI Annual Meeting
AAAAI 2024. New data on neffy (epinephrine nasal spray) include the first report of efficacy after oral food challenge in a pediatric population at risk for anaphylaxis.
Dupilumab Plus Medium-Dose Inhaled Corticosteroid Improved Lung Function and Asthma Control, According to New Data
AAAAI 2024. Patients with asthma who received dupilumab plus medium-dose ICS had improved lung function and asthma control vs those who received placebo plus high-dose ICS.
Dupilumab Effective Up to 5 Years in Adults with Moderate-to-Severe Atopic Dermatitis in Open-Label Extension Study
AAAAI 2024. Reduction of AD signs and symptoms was significant among approximately half of study participants at 4 weeks and continuously rose through week 260, investigators report.
First Study of Oral Mucosal Immunotherapy for Peanut Allergy Elicits Robust Immunologic Response in Adults
AAAAI 2024. Oral mucosal immunotherapy delivered via metered-dose toothpaste produced a statistically significant increase in IgG4 and a decrease in IgE/IgG4 ratio.
Tezepelumab Demonstrates Sustained Post-Treatment Reductions in CSU Disease Activity, Inflammatory Markers
AAAAI 2024. The effects, seen 18 to 20 weeks after discontinuation of tezepelumab, suggest a persistent effect of thymic stromal lymphopoietin (TSLP) blockade in CSU.
Tezepelumab Effective in Severe Asthma Cohorts Stratified by Age at Onset, Inflammatory Phenotype, and Allergen Sensitization
AAAAI 2023. The TSLP inhibitor was superior to placebo in 2 post hoc analyses of the PATHWAY and NAVIGATOR clinical trials.
AAAAI 2023: Pediatric Asthma Risk Score Validated in Multi-cohort Study
Future studies may consider PARS the new gold standard in predicting pediatric asthma risk, said study authors.
For Persons with Asthma Infected with COVID-19, Systemic Corticosteroid Prescribing is Up
AAAAI 2023. Pandemic prescribing rates for systemic corticosteroids increased from Alpha to Delta to Omicron waves of COVID-19 but hospitalizations have dropped, study finds.
AAAAI 2021: Asthma Not an Independent Predictor of Severe COVID-19 Outcomes
Recent research presented at AAAAI 2021 Virtual Annual Meeting suggests asthma is not an independent risk factor for severe COVID-19 or hospitalization.
Significant Reductions in Exacerbations Seen in Broad Population of Severe Asthma Patients
Statistically significant reductions in annual exacerbation rates were seen across baseline eosinophil and exhaled FeNO level and allergy status with telepezumab, in the phase 3 NAVIGATOR trial.
Expert-guided Online Decision Tool Supports Real-time Treatment Choice for Severe Asthma
Treatment for severe asthma may be enhanced using an online decision support tool that draws on expert treatment decisions for a wide variety of potential patient scenarios.
Asthma Patients with COVID-19 at Comparable Risk of Hospitalization
Patients with COVID-19 who have asthma share a similar risk of hospitalization with patients with the infection who do not have asthma, according to new research.
Use of Face Masks Does Not Affect Oxygen Saturation in Asthma Patients
AAAAI Virtual Annual Meeting. Among patients with asthma, wearing a mask, regardless of type or duration of use, had no significant effect on oxygen saturation.
AAAAI 2021 Virtual Annual Meeting: A First Look
Get a first look at key 8 studies to be presented at the upcoming AAAAI 2021 virtual meeting starting this Friday, February 26, 2021.
Biologic Eliminates or Reduces Oral Steroids in Severe Asthma: PONENTE Trial
AAAAI Virtual Annual Meeting. Two-thirds of severe asthma patients dependent upon oral corticosteroids stopped or maximally reduced use, according to the trial data.
